BusinessAgile Therapeutics Announces Pricing of Its Public Offering of Common StockBy Nasdaq OMXJan 22, 2016, 2:17 PM UTC
BusinessNewLink Genetics Presents Phase 1b Data of Indoximod in Combination With Gemcitabine/Nab-Paclitaxel for Patients With Metastatic Pancreatic Cancer That Show Encouraging Durable Responses With Delayed PatternBy Nasdaq OMXJan 22, 2016, 1:00 PM UTC
BusinessK2M Receives CE Mark for Its Next-Generation RHINE(TM) Cervical Disc SystemBy Nasdaq OMXJan 21, 2016, 11:01 PM UTC
BusinessMyriad to Announce Fiscal Second-Quarter 2016 Financial Results on February 2By Nasdaq OMXJan 21, 2016, 9:05 PM UTC
BusinessKeeping a Specimen's Story Straight: The Genesis of a New Product Critical to Preventing Cross-ContaminationBy Nasdaq OMXJan 21, 2016, 8:38 PM UTC
BusinessFive Prime Therapeutics Announces Preliminary Data From the Dose Escalation Portion of the Phase 1 Trial of FPA144 at the ASCO GI Cancers SymposiumBy Nasdaq OMXJan 21, 2016, 8:00 PM UTC
BusinessCancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use in Clinical Trials, Translational Research, and Therapy Selection for PatientsBy Nasdaq OMXJan 21, 2016, 1:00 PM UTC
BusinessSummit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMDBy Nasdaq OMXJan 21, 2016, 12:00 PM UTC
